eIF2B Modulators for Integrated Stress Response Attenuation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as neurodegenerative diseases, leukodystrophies, cancers, inflammatory diseases, and metabolic diseases are inadequate in modulating the integrated stress response (ISR) pathway, particularly through the attenuation of the PERK branch via eIF2B modulation.
Innovation Solution
Development of compounds that activate eIF2B, a component of the ISR pathway, to modulate its activity and attenuate the integrated stress response, thereby treating the aforementioned diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eIF2α is phosphorylated in response to stress signals, then translation initiation is attenuated to help cells cope with stress, but this leads to reduced protein synthesis necessary for cell function and recovery
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to bind to eIF2B and prevent phosphorylated eIF2α from inhibiting its GEF activity. These compounds act as mediators between the stress signal and translation initiation, allowing the cell to maintain protein synthesis while still responding to stress signals through the ISR pathway.
Solution Approach 2:
The patent changes the binding parameters of eIF2B by introducing small molecule ligands that alter the conformational equilibrium of eIF2B, increasing its affinity for GTP and enhancing its GEF activity. This parameter change allows eIF2B to function more effectively even in the presence of phosphorylated eIF2α, thereby maintaining translation initiation during stress response.
2Productivity
If eIF2B activity is enhanced to maintain translation initiation, then protein synthesis is preserved, but this may reduce the cell's ability to mount an effective stress response
Solution Approach 1:
The patent applies partial action by using small molecules that partially activate eIF2B rather than completely overriding its regulation. The compounds increase eIF2B's GEF activity and stability without completely preventing its normal regulatory responses to stress signals, allowing the cell to maintain sufficient translation initiation while preserving stress response capabilities.
Solution Approach 2:
The patent introduces dynamic modulation of eIF2B activity through small molecule binding, which can adjust eIF2B's conformational state and GEF activity in response to cellular conditions. This dynamic control allows the system to balance translation initiation and stress response needs based on the severity and type of stress encountered.
3Reliability
If small molecule compounds are developed to modulate eIF2B activity, then therapeutic benefits can be achieved for various diseases, but the complexity of identifying and optimizing effective compounds increases
Solution Approach 1:
The patent employs structure-activity relationship (SAR) analysis and molecular modeling approaches that allow researchers to predict and optimize compound efficacy based on structural features. This self-service approach to compound optimization reduces the need for extensive trial-and-error experimentation, streamlining the drug development process while maintaining therapeutic efficacy.
Data Source
AI summary
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.